<?xml version="1.0" encoding="UTF-8"?>
<p>Low‐dose aspirin has been proven to be an effective regimen for the prevention of placental complications during pregnancy, including pre‐eclampsia and fetal growth restriction. Intake of low‐dose aspirin during pregnancy is not associated with an increased risk of congenital defects, bleeding or premature closure of the ductus arteriosus
 <xref rid="uog22049-bib-0008" ref-type="ref">8</xref>. The recommended dosage of 150 mg of aspirin daily for the prevention of pre‐eclampsia is based on the results of the ASPRE trial. In the trial, preterm pre‐eclampsia occurred in 1.6% of women in the low‐dose aspirin group, as compared with 4.3% in the placebo group (odds ratio, 0.38; 95% CI, 0.20–0.74; 
 <italic>P</italic> = 0.004)
 <xref rid="uog22049-bib-0008" ref-type="ref">8</xref>.
</p>
